Targeted elimination of prostate cancer by genetically directed human T lymphocytes. - Wikidata - awgldk - TriplyDB

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

http://www.wikidata.org/entity/Q34456721

about

PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models Immunotherapy in metastatic prostate cancer Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγ mice PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses PTEN knockout prostate cancer as a model for experimental immunotherapy Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice.Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor.In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.The promise and potential pitfalls of chimeric antigen receptors.Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells Cell vehicle targeting strategies.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.Genetically engineered T cells to target EGFRvIII expressing glioblastoma.Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.Enhancing adoptive immunotherapy of cancer.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.Targeting the prostate-specific membrane antigen for prostate cancer therapy.Chimeric antigen receptors in cancer immuno-gene therapy: current status and future directions.Reporter gene imaging of immune responses to cancer: progress and challenges.miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade.Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.A new pyrimidine-specific reporter gene: a mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs.Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression.T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

P2860

Q27339832-1642C70C-DB64-4A5D-87DD-025DFC8A8E4D Q28072081-2F2445EF-F869-4ED6-9E63-D9C908CCA9CA Q30503686-F86C9CB0-D557-4022-BFB3-FC17BA8E6577 Q30600094-D4DDA7AD-8D13-46A8-A20B-B786B0F05F58 Q33728431-9A911505-E609-4272-B00C-C70F1721ACCF Q33801773-0F67C72A-CC77-43D2-B401-47A7D6B582E6 Q33833475-415ADA4E-D5E7-421B-9F0F-71F2C5F7004E Q33839836-E7318A3D-6152-4393-85C5-4C65EDC1D52D Q33907262-FCEDACD8-9A46-4C8C-8A05-453F217DA302 Q34048101-C75BAD69-6FBB-4167-B772-0690ADC8A5AA Q34292273-48805DFC-DAB8-41D7-86FC-D344079AED09 Q34970378-CCA56EDD-6CF2-495E-9D09-16E91E3CCEB1 Q35088714-21A1C154-4510-45EF-971A-2F2E944F6F90 Q35216278-7A1A7D0C-A911-4A58-B163-CC8AC3A4B9EC Q35673845-DC1CED70-C3AD-437E-BF22-E2012A7A0351 Q35980893-58402F16-CBFA-4FE2-B8DA-D626EB6B963C Q36299662-E5EC40BA-97E5-4C23-B740-201E26C1B85E Q36300730-3681C752-2981-4B79-A61B-4F8157101C6B Q37120169-B9AF9BCA-8DA9-48E4-A20B-442532C3119A Q37137924-E190CD8A-AA76-4426-87C2-9EC6331C3A1E Q37316117-6040A87A-6592-486D-B857-57221CC8E84D Q37372552-E716BCDD-6A06-4D4D-9D58-5278A7B7709D Q37687429-02CBCBFA-0503-4238-A533-B6B52CC015B4 Q37728639-EB0EC9D9-FCFE-4CC9-A463-8EC7776B9050 Q37751873-EEC45719-3D4A-4DF4-8FF7-83FDABA4CA4A Q37773273-0562AE60-1622-477A-839F-AF46BE878110 Q37952805-E1D98B5F-6D70-49C9-93EF-9A8FE17F3970 Q38003152-EC1188CC-C4EF-4505-952A-589D4658A26D Q38807275-E06B6904-1021-40D3-863B-1F4FED542048 Q38874911-327CC7CC-09AB-4BB3-AE30-82DAA1F82D52 Q39576904-8E67EC66-72C6-46A4-841F-679EE17D59E6 Q39641387-465B9E7E-F264-4C44-A756-6E5CBB7C21BF Q39660810-49D9D236-63D1-4363-A8A6-C289A6B0DBDF Q39835934-84C2B3C2-55E0-4ED2-86A4-0FB34FC27544 Q40047938-854CC14E-33EC-4A69-A2D5-9029F737E33B Q40323802-6D19A540-25CB-47BC-BFD5-89158FA856ED Q40965523-3A9B2885-BB18-443E-A60B-32D94211AF2E Q40981186-F57DD4C0-3C8F-4870-8B48-C756C215A573 Q41613624-607EE31C-8503-4A4F-86B0-56351B9530DC Q42938990-96D2304C-DE65-4CB8-9BD3-3D3DA66834A0

P2860

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

http://www.wikidata.org/entity/Q34456721

description

2005 nî lūn-bûn

@nan

2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@ast

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@en

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@nl

type

label

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@ast

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@en

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@nl

prefLabel

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@ast

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@en

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@nl

P1433

Q34456721-C1FB470C-F6C6-4252-8899-CFA99BA5C913

P1476

Q34456721-BA2B2D1E-7C72-4E2E-8B1E-1B198FA98AFA

P2093

Q34456721-07ABBEDD-5887-45A4-A14B-B9AFB89C60FB

Q34456721-268B7239-4E13-418F-AA3B-D76996697E1C

Q34456721-38EAD34F-0161-42C3-9805-D42612A1B26D

Q34456721-434A136C-7E4B-42F0-8BE3-B14EA741FA01

Q34456721-44425019-4B5E-4BC3-91FE-3C2D42DB4A67

Q34456721-61FE66AB-23DC-472C-99AA-E3BF52962D42

Q34456721-7B24BFCD-FCF2-417A-8938-343FB4E60099

Q34456721-89FFFA65-75E9-42A8-A7CA-ABDCD356D85E

Q34456721-9431CB48-483B-41BE-BF52-9879DB103DA6

Q34456721-97F1E1D0-8DEA-41A0-A927-BBE324A2DD8B

P304

Q34456721-97A84FAF-C69B-41D1-B932-97752832E0F2

P31

Q34456721-F4E8F08A-B88A-400F-B33E-3B5F93BAAD58

P356

Q34456721-F1A1CFDE-D0C1-4264-BFE3-ECDC5D0E3A9C

P407

Q34456721-087890F3-9759-404F-A674-8838C67EA106

P433

Q34456721-3994D8FC-5CA9-4AB8-AFAD-8F7B097E8244

P478

Q34456721-B60C4D51-8285-4F18-8C7C-3B5BE04C756A

P50

Q34456721-92DE53B5-1EAE-4B64-9328-37F6E1131A3E

Q34456721-A414ED73-260B-4C36-8EE4-8BAF21A21437

P577

Q34456721-DB2D5244-8E75-4FB5-8BFD-7671EC61A656

P5875

Q34456721-96AA1FA9-E562-48D9-A07D-82797EF84226

P698

Q34456721-E54CC869-79C2-4358-AC63-075F09B2DCA4

P356

0008-5472.CAN-05-0436

P1433

Cancer Research

P1476

Targeted elimination of prostate cancer by genetically directed human T lymphocytes.

@en

P2093

Clay Lyddane

http://www.w3.org/2001/XMLSchema#string

Elmer Santos

http://www.w3.org/2001/XMLSchema#string

Gertrude Gunset

http://www.w3.org/2001/XMLSchema#string

Ian M Buchanan

http://www.w3.org/2001/XMLSchema#string

Isabelle Rivière

http://www.w3.org/2001/XMLSchema#string

Jason A Koutcher

http://www.w3.org/2001/XMLSchema#string

Jolanta Stefanski

http://www.w3.org/2001/XMLSchema#string

Matthias Stephan

http://www.w3.org/2001/XMLSchema#string

Michael C Gong

http://www.w3.org/2001/XMLSchema#string

Michel Sadelain

http://www.w3.org/2001/XMLSchema#string

P304

9080-9088

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-05-0436

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P50

Aurore Saudemont

Joseph R Osborne

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7561329

http://www.w3.org/2001/XMLSchema#string

P698

16204083

http://www.w3.org/2001/XMLSchema#string